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Current animal models for the evaluation of synthetic grafts are lacking many of the molecu-
lar tools and transgenic studies available to other branches of biology. A mouse model of
vascular grafting would allow for the study of molecular mechanisms of graft failure, includ-
ing in the context of clinically relevant disease states. In this study, we comprehensively
characterise a sutureless grafting model which facilitates the evaluation of synthetic grafts
in the mouse carotid artery. Using conduits electrospun from polycaprolactone (PCL) we
show the gradual development of a significant neointima within 28 days, found to be great-
est at the anastomoses. Histological analysis showed temporal increases in smooth muscle
cell and collagen content within the neointima, demonstrating its maturation. Endotheliali-
sation of the PCL grafts, assessed by scanning electron microscopy (SEM) analysis and
CD31 staining, was near complete within 28 days, together replicating two critical aspects
of graft performance. To further demonstrate the potential of this mouse model, we used
longitudinal non-invasive tracking of bone-marrow mononuclear cells from a transgenic
mouse strain with a dual reporter construct encoding both luciferase and green fluorescent
protein (GFP). This enabled characterisation of mononuclear cell homing and engraftment
to PCL using bioluminescence imaging and histological staining over time (7, 14 and 28
days). We observed peak luminescence at 7 days post-graft implantation that persisted
until sacrifice at 28 days. Collectively, we have established and characterised a high-
throughput model of grafting that allows for the evaluation of key clinical drivers of graft
performance.
Introduction
Coronary artery bypass grafting is a common treatment for revascularisation of ischemic heart
disease, especially in the case of diffuse multi-vessel disease. Autologous conduits such as the
internal mammary artery (IMA) and saphenous vein are most commonly used, with the IMA
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in particular giving exceptional long-term clinical results [1]. However, a large portion of
patients do not have sufficient autologous conduits available due to disease or prior use, mean-
ing bilateral internal mammary grafting is rare, despite it’s proven superiority in treating
multi-vessel disease [2]. Synthetic options such as ePTFE and Dacron, which are successful in
large diameter applications, uniformly fail in low diameter (<6 mm) applications such as in
the coronaries and the peripheries [3]. Significant and ongoing research in regenerative medi-
cine and tissue engineering aims to develop new synthetic conduits, effective for low diameter
revascularisation to meet this need.
Innovation in engineering new conduits relies heavily on animal models for pre-clinical
assessment. An ideal animal model should reflect the human physiological response to vas-
cular grafting, with a focus on the dominant modes of graft failure: neointimal hyperplasia
(NH) and poor endothelialisation [4]. In addition, appropriate animal models should be cost
effective, readily accessible to researchers, and deliver useful endpoints within a reasonable
time frame. Comprehensive review of the literature suggests that the established pre-clinical
pathway for graft evaluation in medium to large animal models should include rabbit and
sheep carotid grafting [5]. However, studies involving medium to large animals are expensive
and require significant expertise and equipment, making them difficult to access for basic
research labs. Small animals are regularly employed as a model of mid-term immune
response and graft remodelling, the most common being the rat abdominal aortic replace-
ment. This model requires long-term time points for NH development and endothelialisa-
tion (at least 3 months). Also absent from this evaluation are established small animal
models which facilitate ready simulation of disease and transgenic strains to study the mech-
anisms of graft failure and the vascular biology underpinning these processes. A mouse
model of vascular grafting which reproducibly manifests the key drivers of graft failure
would be immensely valuable.
Previous mouse grafting models have focused on replacing segments of the abdominal
aorta using end to end suture methods. This approach has been used to evaluate a number of
graft materials including decellularised ovine coronary artery, polyurethane and ePTFE [6].
However, the surgery is technically challenging due to the small diameter of the vessel and the
need for multiple suture points required in a short time frame. It also requires the mobilisation
of the abdominal cavity, which taken together with the location of the abdominal aorta, limit
its compatibility with some non-invasive imaging techniques. Sutureless mouse grafting mod-
els utilising cuff anastomoses have previously been used in the context of vein and aortic trans-
plants in both the carotid and abdominal aorta position [7, 8]. The carotid lies much closer to
the surface making it easier to expose surgically and eliminating the need to temporarily
remove visceral organs. The proximity to the surface also facilitates non-invasive imaging,
including bioluminescent imaging. The utility of this sutureless method was previously shown
using a vein graft in apolipoprotein E knockout (ApoE-/-) mice, following treatment with a
chemokine inhibitor [9]. However, evaluation of synthetic vascular grafts using this method
has yet to be characterised.
In this study, we comprehensively characterise a sutureless interposition grafting model
which facilitates the evaluation of synthetic grafts in the mouse carotid artery. Using conduits
electrospun from poly-caprolactone (PCL) we show the gradual development of a significant
neointima and near-complete endothelialisation within 28 days, together replicating two criti-
cal aspects of graft performance. Furthermore, using longitudinal non-invasive tracking we
characterise the homing and engraftment of luminescent/fluorescent bone-marrow mononu-
clear cells to the PCL graft.
Mouse model of vascular grafting
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Material and methods
Electrospinning
Polyaprolactone (M.W. 80 kDa, Sigma-Aldrich) was dissolved in 1,1,1,3,3,3-hexafluro-2-pro-
panol (HFP) (Sigma-Aldrich) to a final concentration of 10% (w/v). Polymer solutions were
electrospun onto a stainless steel mandrel (0.5 mm diameter) rotating at 500 rpm, at a rate of 2
mL/hr from a 20G flat needle, 20 kV, and an air gap distance of 20 cm. Grafts were sterilised in
ethanol (70%) for 30 mins at room temperature followed by three washes in sterile PBS.
Mouse carotid grafting
All procedures were approved by the Sydney Local Heath District Animal Welfare Committee,
protocol number 2015/016A. Experiments were conducted in accordance with the Australian
Code of Practice for the Care and Use of Animals for Scientific Purpose. All personnel
involved in the animal procedures have completed an approved animal care and ethics course.
C57/BL6 mice (male, 9–10 weeks old, 25 ± 2 g) were purchased from Animal Resources
Centre (Canning Vale, WA, Australia). One week before the surgery, the drinking water of
mice were supplemented with aspirin (10 mg/kg/d). The cuff procedure was carried out as pre-
viously described [10] to implant synthetic graft materials into the carotid position. Briefly, the
mice were anaesthetised with methoxyflurane (2%) and placed in a supine position. The right
common carotid artery was mobilised and double ligated at the midpoint then dissected. Poly-
imide cuffs (Cole-Parmer) were placed around each end of the arteries and clamped. Over
hanging arteries were everted on the plastic cuff and secured with 8–0 silk sutures to form the
anastomoses. PCL grafts were sleeved over each end and secured with 8–0 sutures. Clamps
were removed and blood flow was confirmed with pulsation. The skin was closed with 6–0 silk
sutures and mice allowed to recover with food and water ad libitum. Mice received analgesic
in the form of a single dose of carprofen (5 mg/kg) immediately post-surgery. The mice were
monitored daily for five consecutive days post-surgery for signs of discomfort and adminis-
tered additional analgesic if necessary. Mice that sustained a weight loss of 15% of the pre-sur-
gery weight or had markedly reduce mobility were sacrificed by cervical dislocation.
Recipient mice were sacrificed at 7, 14 and 28 days after implant. The mice were anaesthe-
tised with methoxyflurane (2%) and sacrificed by cardiac puncture. Finally, mice were per-
fused with heparinised saline and the grafted carotid artery was isolated and dissected
proximal and distal to the graft.
The survival rate of the procedure was 83% (40 of 48), and procedure time 40±5 mins.
Cause of death of the 8 mice were due to surgical mistakes leading to arterial rupture. 4 grafts
were found to be occluded after explant and these samples were excluded from the study. Of
the 36 grafts included in the study, 9 samples for each timepoint in C57/BL6 (7 for histological
analysis and 2 for open graft SEM) and 3 samples for each timepoint in FVB/N were used.
Cell tracking
Isolation of donor BM-MNCs. Transgenic mice over expressing both firefly luciferase
and enhanced green fluorescent protein (eGFP) (FVB-L2G) were purchased from Jackson
Laboratories (Bar Harbor, ME, USA). Isolation of BM-MNCs was carried out as previously
described [11]. The tibias and femurs from donor FVB-L2G mice (female, 7–8 weeks old, ~ 20
g) were explanted and flushed using a 21-gauged needle with sterile PBS. The bone marrow
was then layered on top of Lympholyte1-M cell separation media (6 mL per one pair of tibia
and femur) and centrifuged at 1250 × g for 25 minutes with deceleration off. The resulting
buffy coat was aspirated and washed three times in sterile PBS: 800 × g for 10 mins, 500 × g for
Mouse model of vascular grafting
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10 mins, and 200 × g for 10 mins. Following the last wash, the pellet of BM-MNCs was resus-
pended in endothelial basal medium (phenol free) to desired cell concentrations.
Bioluminescence imaging. FVB mice (male, 8–9 weeks old, 25 ± 2 g) were purchased
from Australian BioResources (Moss Vale, NSW, Australia). Carotid grafting surgery was per-
formed and the animals were allowed to recover before BM-MNCs (1 × 106 cells) were admin-
istered via tail vein injection on the same day. D-luciferin was reconstituted at a concentration
of 40 mg/ml. To induce bioluminescence, luciferin was given at a total volume of 200 μL via
intra-peritoneal injection. Bioluminescence was quantified using the IVIS Series pre-clinical in
vivo imaging system apparatus (Perkin Elmer). Grafts were explanted at 7, 14 and 28 days
post-surgery.
Histology
Explanted grafts from C57/BL6 mice were fixed overnight in paraformaldehyde (2%) at room
temperature. Samples were dehydrated through an ethanol gradient and embedded in paraffin
and sectioned at 5 μm transversely from proximal anastomosis to distal anastomosis. Paraffin
sections were deparaffinised and rehydrated for haematoxylin and eosin staining and Carstairs
staining. For immunohistochemistry staining, sections were deparaffinised and stained with
antibodies against SM α-actin (Sigma-Aldrich, a5691, 1:250) and smooth muscle myosin
heavy chain 11 (Abcam, ab53219, 1:200) for smooth muscle cells and CD31 (Abcam, ab28364,
1:200) for endothelial cells.
Explanted grafts from FVB-N mice were fixed overnight in paraformaldehyde (2%) at
room temperature. Fixed samples were placed in sucrose (30%) for 48 h then embedded in
OCT and sectioned at 40 μm. Sections were then stained using standard free-floating tech-
niques with an anti-GFP antibody (Sapphire Bioscience, GTX26662, 1:100).
Scanning electron microscopy
Electrospun grafts were gold sputter coated (20 nm) and imaged with a JEOL Neoscope Table-
top scanning electron microscopy. For quantification, the widths of 40 fibres were measured
within an image for a total of 10 images. Explanted grafts were cut open longitudinally then
fixed overnight in paraformaldehyde (2%) at room temperature followed by glutaraldehyde
(2.5%) for one hour at room temperature. Samples were then post-fixed with osmium tetraox-
ide in 0.1 M PB, and dehydrated through an ethanol gradient before drying with hexamethyl-
disilasane. Samples were gold sputter coated and imaged with a Zeiss Sigma VP FEG scanning
electron microscopy.
Quantitative analysis
Analysis of histological stains was done with ImageJ. Paraffin sections of the graft were selected
from 5 points evenly distributed along the graft. From each of these points, 3 slides were
selected 5 slides apart and one tissue section from each slide was analysed. Neointima area was
quantified represented as a percentage of total lumen area defined by the inner graft wall. SMC
content was quantified by measuring the area of SM α-actin using a constant threshold inten-
sity and expressed as a percentage of the neointima area. Similarly, collagen was quantified
and expressed as a percentage of the neointima area. Endothelial coverage was quantified by
measuring the length of CD31 positive staining along the lumen and expressed as a percentage
of the total luminal circumference. GFP+ cell counts were quantified using 10 sections evenly
distributed along the graft.
Mouse model of vascular grafting
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Statistical analysis
Data are expressed as mean ± SEM and indicated in figures as  p<0.05,  p<0.01,
p<0.001, and p<0.0001. The data were compared using ANOVA using GraphPad
Prism version 6 (Graphpad Software, San Diego, California).
Results
Graft characterisation
Highly uniform PCL conduits were electrospun with an inner diameter of 500 μm and wall
thickness of 100 μm (Fig 1A). Under scanning electron microscopy, the luminal surface and
fibrous structure were evident (Fig 1B). At higher magnification, randomly aligned rounded
fibres were observed (Fig 1C). Quantification of the fibre characteristics revealed an average
fibre diameter of 0.39 ± 0.01 μm, tightly distributed in a range from 0.3–0.49 μm (Fig 1D).
Surgical procedure
The right common carotid artery was mobilised (Fig 2A), care was taken to avoid the vagus
nerve and disruption of other microvasculature. Two ligations at the midpoint of the artery
Fig 1. Characterisation of electrospun PCL graft. A: Macroscopic image of PCL graft. B: Scanning electron microscopy images of
a transverse cross section. Scale bar = 200 μm C: Scanning electron microscopy images of electrospun fibres on the luminal side.
Scale bar = 10 μm. D: Histogram of fibre diameter distribution.
https://doi.org/10.1371/journal.pone.0174773.g001
Mouse model of vascular grafting
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were made as close as possible to maximise the length of artery (Fig 2B). After dissecting
between the ligations, cuffs were guided onto each end of the artery and clamped with ligated
artery protruding (Fig 2C). The overhanging artery was everted and secured on the cuff with a
suture (Fig 2D), forming the anastomoses. PCL grafts were sleeved over the everted cuffs and
secured (Fig 2E). Clamps were released from the distal side then proximal (Fig 2F).
Neointimal hyperplasia
Area. We began by systematically quantifying the neointimal area throughout the grafts at
7, 14 and 28 days. At each time point, we observed a distribution of a developing neointima
along the length of the grafts. The neointimal area was greatest at the anastomoses and lowest
towards the mid-section (Fig 3A). At 28 days, this effect was most pronounced and the extent
of neointimal hyperplasia greatest near the proximal cuff. Neointima cellularity showed a simi-
lar trend (S1 Fig) Looking at the temporal increase in hyperplasia at the proximal cuff, neointi-
mal area increased from 32.0 ± 3.7% at day 7 to 44.4 ± 4.7% at day 14 and 54.1 ± 4.0% at day 28
post-surgery (p<0.0001). Representative images demonstrate the progressive increase in
hyperplasia area (Fig 3B).
Smooth muscle cell content. SMCs are a major component of the neointima. Smooth
muscle (SM) α-actin is a marker of SMCs [12]. The distribution of SM α-actin followed the
same trends seen for neointimal area, such that there were more SM α-actin+ cells at the anas-
tomoses and less towards the mid-graft (Fig 4A). Also, consistent with the total hyperplasia
Fig 2. Mouse carotid grafting procedure with corresponding schematic diagram (adapted from [7]). A: Carotid artery was
isolated. B: Double ligation at the mid-point. C: Cuffs were placed on each end of the ligation. D, E: Clamps were applied and artery
segment was everted over the cuff and fixed in place with suture. F: Graft was secured to each ends of the cuffs. G: Clamps were
removed and blood flow confirmed.
https://doi.org/10.1371/journal.pone.0174773.g002
Mouse model of vascular grafting
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area, the percentage of average SM α-actin increased significantly from 1.6 ± 0.4% at day 7 to
7.5 ± 1.2% at day 14 post-surgery. SM α-actin+ area continued to increase up to day 28 post-
surgery to 15.5 ± 1.7% of the neointimal area. Within the neointima, SM α-actin was observed
predominately on the luminal side of the neointima (Fig 4B). Contractile smooth muscle cells
(myosin heavy-chain positive) were only evident at day 28 post-surgery, confined to the proxi-
mal and distal regions.
Collagen content. Collagen is a major component of newly deposited extracellular matrix
(ECM), formed during neointima development. Changes to the collagen distribution through-
out grafts within a single timepoint was less varied than the neointima or SM α-actin areas,
Fig 3. Neointimal area. A: Distribution of NH throughout the graft. Neointimal area represented as a percentage of total luminal area
as defined by the inner graft wall. Data expressed as mean ± SEM and analysed using two-way ANOVA, n = 7 animals/timepoint. B:
Representative images of H&E staining of cross sections. Black dotted lines indicate the graft wall. Scale bar = 100 μm.
https://doi.org/10.1371/journal.pone.0174773.g003
Mouse model of vascular grafting
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but most evident at day 28 (Fig 5A). The average total collagen content throughout the graft
increased significantly from 7.3 ± 1.0% at day 7 to 25.3 ± 2.1% at day 14 and then 34.8 ± 2.2 at
day 28 post-surgery. Representative images showing the distribution of collagen (stained blue)
at each time point (Fig 5B).
Endothelialisation
Endothelial cells line arterial walls, providing a non-thrombogenic surface and which also sup-
presses neointimal hyperplasia. We first examined the cell coverage of implanted grafts at days
7, 14 and 28 post-grafting using SEM (Fig 6A). While the underlying fibrous PCL graft struc-
ture is covered at all timepoints, rounded cells and an incomplete surface layer can be seen at
days 7 and 14 post-grafting, before a completely uniform cell layer is observed at day 28. To
Fig 4. Smooth muscle α-actin content in the neointima. A: Distribution of SM α-actin area throughout the graft. SM α-actin area
represented as a percentage of the neointimal area. Data expressed as mean ± SEM and the average SM α-actin content along the
length of the graft was analysed using one-way ANOVA, n = 7 animals/timepoint. B: Representative images of cross sections with
SM α-actin stained in red, nucleus in blue. Black dotted lines indicate the graft wall. Scale bar = 100 μm.
https://doi.org/10.1371/journal.pone.0174773.g004
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definitively identify and quantify graft endothelialisation, we used CD31 immunohistochemis-
try. We observed clear differences in endothelial cell distribution throughout the grafts, most
evident at day 7, and remaining prominent at day 14 (Fig 6B). At both these timepoints,
endothelialisation is greatest at the anastomoses and least in the mid-graft, with no endothelial
cells detected in the mid-graft at day 7. By day 28 post-grafting, cell coverage was uniform
throughout the grafts. Direct comparison of the endothelialisation of the mid-grafts exempli-
fied the time dependant increase, with no CD31 staining detected at 7 days, partial coverage of
Fig 5. Total collagen content in neointima. A: Distribution of total collagen throughout the graft area represented as a percentage
of the neointimal area. Data expressed as mean ± SEM and the average collagen content along the length of the graft was analysed
using one-way ANOVA, n = 7 animals/timepoint. B: Representative images of Carstair histological stain of cross sections, collagen in
blue, muscle in red. Black dotted lines indicate the graft wall. Scale bar = 100 μm.
https://doi.org/10.1371/journal.pone.0174773.g005
Mouse model of vascular grafting
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Fig 6. Endothelialisation. A: Scanning electron microscopy images of the luminal side of the graft. Scale
bar = 500 μm. Inset scale bar = 50 μm. B: Quantification of CD31 coverage represented as a percentage of
total luminal circumference. Data expressed as mean ± SEM and the mid section of the grafts were analysed
using one-way ANOVA, n = 7 animals/timepoint. C: Representative images of cross sections with CD31
staining in red, nucleus in blue. White dotted lines indicate the graft wall. Scale bar = 100 μm.
https://doi.org/10.1371/journal.pone.0174773.g006
Mouse model of vascular grafting
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28.8 ± 7.0% at 14 days increasing to 78.5 ± 6.7% by 28 days. Representative images show CD31
positive cells in red (Fig 6C).
Cell tracking
Bioluminescent and eGFP+ bone marrow mononuclear cells (BM-MNCs) from FVB-L2G
mice were injected into FVB-N control recipient mice that had undergone carotid graft sur-
gery (Fig 7A). The temporal and spatial distribution of injected BM-MNCs was tracked non-
invasively using IVIS bioluminescent imaging (Fig 7B). Bioluminescence was localised to the
carotid area with a more intense signal at 7 days compared to 14 and 28 days. To confirm the
presence of injected cells at the graft site, explanted grafts were stained for eGFP. eGFP positive
cells were observed at all three time points in the granular tissue surrounding the graft (Fig
7C). Consistent with the bioluminescence signal, quantification of eGFP positive cells showed
the highest number of cells at 7 days (545 ± 42), reduced to 258 ± 27 at 14 days, but persistent
to 28 days (250 ± 59) (Fig 7D).
Discussion
In this study, we have comprehensively characterised a mouse model of carotid artery vascular
grafting, demonstrating mimicry of clinically important endpoints, including neointimal
hyperplasia and endothelialisation. We additionally show the promise of using transgenic
mice to bring valuable new tools to the investigation of synthetic graft materials. We chose to
validate our model system using electrospun PCL grafts, which have been well characterised
previously as rat abdominal aorta replacements [13, 14]. PCL remains a widely used synthetic
polymer in tissue engineering because of its controlled degradation, low inflammatory profile
and high mechanical strength [13, 15]. The use of cuff anastomoses in the procedure allows for
low diameter conduits to be grafted where traditional end to end suture grafting is not feasible.
Grafting in the carotid position has implicit advantages over aortic replacement, facilitating
the use of non-invasive imaging techniques.
An ideal grafting model should be reflective of the human physiological response to vascu-
lar replacement. To characterise this vascular grafting model, we quantified neointima pro-
gression and composition and the rate of endothelialisation. In humans, NH initially develops
at the anastomoses of small diameter grafts, where the grafted segment joins the native vascula-
ture [16]. This pattern of NH progression has been linked to flow disturbances and compliance
mismatch between the native artery and inelastic synthetic materials. Reflecting this pathology,
our model showed that NH developed at the anastomoses and decreased towards the mid-sec-
tion, with the greatest NH at the proximal anastomosis. Clinically, restenosis is defined as 50%
occlusion of the lumen of a vessel [17]. In our model, neointimal area gradually increases and
reached 53% of the total lumen area by 28 days. SM α-actin and collagen quantification suggest
that the hyperplasia is stabilising over time. Compared to other established animal models,
such as rat abdominal aorta (3 months) and sheep carotid artery (6 months) [18, 19], the short
timeframe of our model is a significant advantage for screening novel synthetic grafts.
The endothelium lining the luminal surface of native vessels actively maintains haemostasis,
not only by masking thrombogenic components of the subendothelial connective tissue but
also by expressing anti-clotting compounds, including nitric oxide [20]. A complete endothe-
lium is also a critical determinant of vascular lesion formation and areas of injury that rapidly
endothelialise have significantly less intimal thickening and restenosis [21]. The clinical perfor-
mance of synthetic grafts is thus highly dependent on the degree and speed of endothelialisa-
tion. Our model shows progressive endothelialisation starting from the anastomoses, evident
by day 7. Increases in coverage were observed by 14 days, but the mid-graft was not covered
Mouse model of vascular grafting
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Fig 7. Cell tracking. A: Schematic of experimental design. Bone marrow mono-nuclear cells are isolated from
FVB-L2G mice and injected into FVB-N mice that received that carotid grafting. B: Representative IVIS images
of carotid grafted mice with BM-MNC injection. Warm colours denote higher signal and cold colours denote
lower signal. C: Representative images of cross sections with eGFP staining in green and nucleus in blue. Scale
bar = 100 μm. D: Quantification of eGFP positive cells cells. Data expressed as mean ± SEM and analysed
using one-way ANOVA, n = 3 animals/timepoint.
https://doi.org/10.1371/journal.pone.0174773.g007
Mouse model of vascular grafting
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until 28 days. Again, this process occurred in a compressed timeframe, much quicker than the
3 months required for full coverage in rat abdominal aorta grafting [14]. Further, we have iden-
tified timepoints where coverage is incomplete (7 and 14 days), allowing for evaluation of syn-
thetic grafts which propose to accelerate endothelialisation. Our model appears to support the
ingrowth of endothelium from the anastomotic regions, given the observed mode of progres-
sion. However, we recognise that circulating endothelial progenitor cells substantially contrib-
ute to prosthesis endothelialisation [22], making them important mediators of implant
compatibility. Their contribution could readily be determined in this mouse model using estab-
lished bone marrow grafting techniques [23]. The mechanism and time course of endotheliali-
sation of our model appear superior to other previous animal models such as canine models
which are now seldom used in the field due to spontaneous endothelialisation [5].
Apart from the benefits of low cost and high through put intrinsic to a mouse model, there
is also a range of molecular and cellular imaging tools available that have not been fully devel-
oped for larger animal models. To begin exemplifying the potential of our model, we injected
bioluminescent BM-MNCs derived from FVB-L2G mice and tracked their homing to and
engraftment in transplanted PCL grafts. The dual eGFP/luciferase reporters in these cells allow
for serial, non-invasive imaging of the cells in live mice, supported by traditional immunohis-
tochemistry analysis. The intense signal observed around the graft at 7 days shows significant
BM-MNC homing, while the persistence of bioluminescent at 28 days suggested cell engraft-
ment, validated with positive eGFP staining. This approach has great promise for increasing
our understanding the contributions of stem cell containing populations towards tissue regen-
eration, which while therapeutically promising, have not reached their clinical potential [11].
Importantly, this also provides a valuable tool for the guided development of new synthetic
vascular grafts which have enhanced interaction with stem cell therapy.
More broadly, our model enables future evaluation of new synthetic conduits in a range of
established disease models relevant to graft failure and prevalent in patients regularly requiring
revascularisation of small diameter vessels [1]. Transgenic and knockout mouse strains includ-
ing those which demonstrate accelerated atherosclerosis (ApoE-/-) [24], simulate obesity/dia-
betes (db/db) [25], or altered eNOS expression [26], have immediate relevance to a more
comprehensive evaluation of new graft materials. Mechanistically, the role of inflammatory
cells (e.g. macrophages), immune cells (e.g. T cells) and cytokines (e.g. TNFα) in the progres-
sion of graft hyperplasia could also be more fully explored [27]. Taken together, grafting of
synthetic conduits in a mouse coronary artery will dramatically change the research questions
that can be asked in this area, facilitating improved developed of new materials, thereby
addressing a long-standing unmet need in vascular surgery.
Conclusion
In conclusion, we have established a mouse model of vascular grafting that recapitulates clini-
cally relevant features within 28 days. Exemplifying the potential of the model, we showed the
non-invasive tracking of BM-MNCs homing and engrafting by utilising a transgenic strain
encoded with Luc/GFP dual reporter. We believe this model is a useful tool facilitating the
evaluation of novel synthetic grafts.
Supporting information
S1 Fig. Neointima cellularity. Nuclei count of neoinitma using haematoxylin stain. Data
expressed as mean ± SEM and the average nuclei count along the length of the graft was ana-
lysed using one-way ANOVA, n = 7 animals/timepoint.
(TIF)
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S2 Fig. Contractile smooth muscle cells in neointima. Representative images of cross section
with smooth muscle myosin heavy chain 11 stained in red and nucleus in blue. White dotted
lines indicate the graft wall. Scale bar = 100 μm.
(TIF)
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